Key facts
- This page summarizes Ramesh Kumar's Form 4 filing for Ocugen, Inc. (OCGN).
- 3 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 20 Apr 2022, 16:03.
Ramesh Kumar - 18 Apr 2022 Form 4 Insider Report for Ocugen, Inc. (OCGN)
- Role
- Director
- Signature
- Ramesh Kumar by Shankar Musunuri, his attorney-in-fact
- Issuer symbol
- OCGN
- Transactions as of
- 18 Apr 2022
- Net transactions value
- -$17,400
- Form type
- 4
- Filing time
- 20 Apr 2022, 16:03:01 UTC
- Previous filing
- 20 Jan 2022
- Next filing
- 08 Jun 2022
- SEC
- View on sec.gov
Key filing fact
Ramesh Kumar filed Form 4 for Ocugen, Inc. (OCGN) on 20 Apr 2022.
Change
- Previous filing in this sequence was filed on 20 Jan 2022.
- Current net transaction value: -$17,400.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Transactions Table
OCGN
transaction
Common Stock
Options Exercise
- Transaction value
- $3,825
- Shares
- +7,500
- Change %
- Price
- $0.5100
- Shares after
- 7,500
- Date
- 18 Apr 2022
- Ownership
- Direct
OCGN
transaction
Common Stock
Sale
- Transaction value
- $21,225
- Shares
- -7,500
- Change %
- -100%
- Price
- $2.83*
- Shares after
- 0
- Date
- 18 Apr 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
OCGN
transaction
Derivative
Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- +7,500
- Change %
- +83%
- Price
- $0.000000
- Shares after
- 16,500
- Date
- 18 Apr 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- $0.5100
- Footnotes
- F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
| F2 | The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.79 to $2.89. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| F3 | The options, initially representing a right to purchase 54,000 shares, vest and become exercisable in equal monthly installments over three years commencing on February 2, 2020, subject to continued service with the Company on the applicable vesting dates. |